ISRCTN47578325 https://doi.org/10.1186/ISRCTN47578325

Evaluation of melatonin therapy on sleep and delirium in intensive care patients

Submission date	Recruitment status	[ ] Prospectively registered
12/09/2003	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
12/09/2003	Completed	[X] Results
Last Edited	**Condition category**	[ ] Individual participant data
08/09/2008	Nervous System Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Richard Bourne

Contact details
STH NHS Trust
Critical Care
Royal Hallamshire Hospital
Sheffield
United Kingdom
S10 2JF
+44 (0)114 271 3036
richard.bourne@sth.nhs.uk

Additional identifiers

Protocol serial number
N0059122216

Study information

Scientific Title

Study objectives
1. To evaluate the effect of melatonin therapy on the sleep characteristics of intensive care patients.
2. Secondary objectives include studying the incidence of delirium and bispectral index score between patients receiving melatonin or placebo.

Ethics approval required
Old ethics approval format

Ethics approval(s)
South Sheffield Research Ethics Committee (UK) on 09/01/03.

Study design
Single centre randomised controlled trial

Primary study design
Interventional

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Nervous System Diseases: Sleep disorders

Interventions
Melatonin versus placebo.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
melatonin

Primary outcome(s)
Sleep and delirium.

Key secondary outcome(s))
No secondary outcome measures

Completion date
30/04/2006

Eligibility

Key inclusion criteria
Patients admitted to the adult general intensive care unit with acute respiratory failure requiring mechanical ventilation and then a tracheostomy to assist weaning.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
Not Specified

Key exclusion criteria
1. Expected length of stay of less than five further days
2. Previously treated for sleep disturbances
3. Not receiving target enteral feed volume or aspirates greater than 200mls
4. Previous history of convulsions
5. Psychiatric or neurological disease
6. Excessive alcohol consumption (equal to or greater than 50 units per week)
7. Recreational drug use
8. Sleep apnoea
9. Severe heart failure (NYHA III/ IV)
10. Sedative infusions must have been discontinued for more than 24 hours (propofol and alfentanil) or more than 36 hours (morphine and midazolam) with a Sedation Agitation Score (SAS) > 3

Date of first enrolment
01/04/2003

Date of final enrolment
30/04/2006

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
STH NHS Trust
Sheffield
United Kingdom
S10 2JF

Sponsor information

Organisation
Department of Health (UK)

Funder(s)

Funder type
Government

Funder Name
Sheffield Teaching Hospitals - Central Campus (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2008		Yes	No